An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis
Sign Up to like & getrecommendations! Published in 2019 at "Hepatology"
DOI: 10.1002/hep.31046
Abstract: Interleukin‐22 has beneficial effects on inflammation and impaired hepatic regeneration that characterize alcohol‐associated hepatitis (AH). F‐652 is a recombinant fusion protein of human interleukin‐22 and immunoglobulin G2 fragment crystallizable. This study aims to assess the… read more here.
Keywords: associated hepatitis; alcohol associated; safety efficacy; 652 patients ... See more keywords
A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults.
Sign Up to like & getrecommendations! Published in 2021 at "Vaccine"
DOI: 10.1016/j.vaccine.2020.12.062
Abstract: BACKGROUND This first in human study was designed as an open label clinical trial to assess the safety and tolerability of Serum Institute of India Pvt. Ltd. (SIIPL) Tdap vaccine in healthy adult volunteers, aged… read more here.
Keywords: clinical trial; tdap vaccine; assess safety; serum institute ... See more keywords
OP87 Nitrous Oxide As Sedation Regimen In Children—How To Assess Safety?
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462318001228
Abstract: Introduction: Children who undergo short, painful procedures at hospitals are given different kinds of pain relief (analgesics), often in combination with drugs for relaxation (sedatives). Nitrous oxide (NO) is a drug administered for pain relief… read more here.
Keywords: nitrous oxide; safety; sedation; assess safety ... See more keywords
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02537-17
Abstract: ABSTRACT DS-2969b is a novel GyrB inhibitor in development for the treatment of Clostridium difficile infection (CDI). The aim of this study was to assess the safety, tolerability, pharmacokinetics, and effects on the normal gastrointestinal… read more here.
Keywords: study assess; study; 2969b novel; novel gyrb ... See more keywords